Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Cipla
Express Scripts
Medtronic
Johnson and Johnson
McKesson
Fuji
Federal Trade Commission
Argus Health
McKinsey

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,993,761

« Back to Dashboard

Summary for Patent: 8,993,761
Title:Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period.
Inventor(s): Bando; Takuji (Tokushima, JP), Aoki; Satoshi (Tokushima, JP), Kawasaki; Junichi (Tokushima, JP), Ishigami; Makoto (Tokushima, JP), Taniguchi; Youichi (Tokushima, JP), Yabuuchi; Tsuyoshi (Tokushima, JP), Fujimoto; Kiyoshi (Tokushima, JP), Nishioka; Yoshihiro (Tokushima, JP), Kobayashi; Noriyuki (Tokushima, JP), Fujimura; Tsutomu (Tokushima, JP), Takahashi; Masanori (Tokushima, JP), Abe; Kaoru (Tokushima, JP), Nakagawa; Tomonori (Tokushima, JP), Shinhama; Koichi (Tokushima, JP), Utsumi; Naoto (Tokushima, JP), Tominaga; Michiaki (Tokushima, JP), Ooi; Yoshihiro (Tokushima, JP), Yamada; Shohei (Toksuhima, JP), Tomikawa; Kenji (Tokushima, JP)
Assignee: Otsuka Pharamceutical Co. Ltd. (Tokyo, JP)
Application Number:13/749,753
Patent Claim Types:
see list of patent claims
Formulation; Process;

Drugs Protected by US Patent 8,993,761

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Otsuka Pharm Co Ltd ABILIFY MAINTENA KIT aripiprazole FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 202971-001 Feb 28, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Otsuka Pharm Co Ltd ABILIFY MAINTENA KIT aripiprazole FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 202971-003 Sep 29, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Otsuka Pharm Co Ltd ABILIFY MAINTENA KIT aripiprazole FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 202971-002 Feb 28, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Otsuka Pharm Co Ltd ABILIFY MAINTENA KIT aripiprazole FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 202971-004 Sep 29, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,993,761

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2001-290645Sep 25, 2001
Japan2001-348276Nov 14, 2001
Canada2379005Mar 27, 2002

Non-Orange Book US Patents Family Members for Patent 8,993,761

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,910,589 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Try a Free Trial
8,580,796 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Try a Free Trial
8,901,303 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Try a Free Trial
8,642,760 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Try a Free Trial
8,703,773 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Try a Free Trial
9,359,302 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Try a Free Trial
8,901,130 Low hygroscopic aripiprazole drug substance and processes for the preparation ➤ Try a Free Trial
8,703,772 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Try a Free Trial
8,017,615 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Try a Free Trial
8,399,469 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,993,761

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 033485 ➤ Try a Free Trial
Argentina 056503 ➤ Try a Free Trial
Argentina 073111 ➤ Try a Free Trial
Argentina 077635 ➤ Try a Free Trial
Argentina 087544 ➤ Try a Free Trial
Austria 322269 ➤ Try a Free Trial
Austria 464050 ➤ Try a Free Trial
Austria 465736 ➤ Try a Free Trial
Austria 465737 ➤ Try a Free Trial
Austria 467416 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Farmers Insurance
Dow
Accenture
Johnson and Johnson
Baxter
Teva
Chinese Patent Office
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot